688443 Chongqing Genrix Biopharmaceutical
- 37.27
- -0.41-1.09%
Chongqing Genrix Biopharmaceutical News
Zhixiang Jintai (688443.SH): At the end of the term, Jiang Ren, the actual controller, increased the company's shares by about 31.22,200 yuan
Gelonghui, May 17, 丨 Zhixiang Jintai (688443.SH) announced that as of May 16, 2024, the actual controller, Mr. Jiang Rensheng, had increased his holdings of the company's 875,582 shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for about 0.24% of the company's total issued share capital. The total increase amount amount of about RMB 31.22,200 million has been reached, reaching the lower limit of the increase range of RMB 30 million. The period of this increase plan has expired and the implementation of the increase in holdings has been completed.
Is Chongqing Genrix Biopharmaceutical (SHSE:688443) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Zhixiang Jintai (688443.SH) reported first-quarter results with a net loss of 164 million yuan
Zhixiang Jintai (688443.SH) released its report for the first quarter of 2024, with revenue of 6,330.27...
Guoxin Securities: The pharmaceutical industry is entering an upward inflection point in the medium to long term, and focus on high growth targets in the quarterly report in the short term
The pharmaceutical industry currently has low growth, low profitability, undervaluation, and low transaction attention, and is entering a major layout range at an upward inflection point in the medium to long term.
Private Equity Firms in Chongqing Genrix Biopharmaceutical Co., Ltd. (SHSE:688443) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 15% Last Week
Key Insights The considerable ownership by private equity firms in Chongqing Genrix Biopharmaceutical indicates that they collectively have a greater say in management and business strategy The larg
Guoxin Securities: Focus on the immediate needs of medical care, focus on the high growth targets of the first quarter report
The pharmaceutical industry currently has low growth, low profitability, undervaluation, and low transaction attention, and is entering a major layout range at an upward inflection point in the medium to long term.
Chongqing Genrix Biopharmaceutical Co., Ltd.'s (SHSE:688443) Intrinsic Value Is Potentially 100% Above Its Share Price
Key Insights The projected fair value for Chongqing Genrix Biopharmaceutical is CN¥61.83 based on 2 Stage Free Cash Flow to Equity Chongqing Genrix Biopharmaceutical is estimated to be 50% undervalu
Zhixiang Jintai (688443.SH): GR2102 injection obtained drug clinical trial approval notice
Zhixiang Jintai (688443.SH) announced that the company received the approval and issuance of the “Clinical Pharmacology...” issued by the State Drug Administration
Zhixiang Jintai (688443.SH): GR1802 Injection Obtains Drug Clinical Trial Approval Notice for Allergic Rhinitis Indications
Gelonghui, Feb. 2: Zhixiang Jintai (688443.SH) announced that the company received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the clinical trial application for allergic rhinitis indications of the product GR1802 injection under development was approved. GR1802 injection is a novel recombinant all-human anti-interleukin 4-receptor α (IL-4Rα) monoclonal antibody injection independently developed by the company. It can selectively bind IL-4Rα, block IL-4 and IL13 signaling pathways, regulate type 2 immunity, and reduce eosinophil and IgE levels.
Zhixiang Jintai (688443.SH): The actual controller increased the company's shares by a total of 17.044,900 yuan
Gelonghui, December 26, 丨 Zhixiang Jintai (688443.SH) announced that from November 17, 2023 to December 25, 2023, the actual controller, Mr. Jiang Rensheng, increased his holdings of the company's shares by 475,582 shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for about 0.13% of the company's total issued share capital, with a total increase of about 17.044,900 yuan.
Zhixiang Jintai (688443.SH): 6.273 million restricted shares will be listed and distributed from December 20
On December 11, Gelonghui announced that Zhixiang Jintai (688443.SH) announced that the number of shares that the company has lifted sales restrictions and applied for listing is 62729.97 million shares. This part of the restricted shares will be listed and distributed from December 20, 2023.
Zhixiang Jintai (688443.SH): GR1802 injection initiates phase III clinical trial for moderate and severe atopic dermatitis indications
Zhixiang Jintai (688443.SH) issued an announcement. Recently, the company “An evaluation of GR1802 injections in...
Jiang Rensheng, the actual controller of Zhixiang Jintai (688443.SH), plans to spend 30 million yuan to 50 million yuan to increase his holdings
Zhixiang Jintai (688443.SH) announced that Jiang Rensheng, the actual controller of the company, plans to use his own funds or raise his own funds...
Private Equity Firms Invested in Chongqing Genrix Biopharmaceutical Co., Ltd. (SHSE:688443) Copped the Brunt of Last Week's CN¥484m Market Cap Decline
Key Insights Chongqing Genrix Biopharmaceutical's significant private equity firms ownership suggests that the key decisions are influenced by shareholders from the larger public Chongqing Zhirui In
Zhixiang Jintai (688443.SH) released the first three quarter results, with a net loss of 568 million yuan
Zhixiang Jintai (688443.SH) disclosed the report for the third quarter of 2023. The company achieved revenue of 14 in the first three quarters...
Anxin Securities: Innovative drugs in the field of self-exemption have entered a cash out period and the atopic dermatitis market is about to rise
Atopic dermatitis (AD) is one of the most common chronic inflammatory pruritus diseases. Under the neutral hypothesis, the bank expects the domestic medium to severe atopic dermatitis market to reach 29.1 billion yuan by 2030.
Zhixiang Jintai (688443.SH) released semi-annual results, with a net loss of 388 million yuan, an increase over the previous year
Zhixiang Jintai (688443.SH) disclosed the 2023 semi-annual report. The company achieved revenue of 13.2 during the reporting period...
Zhi Xiang Jintai (688443.SH): The actual controller and controlling shareholder extended the share lockdown period until December 19, 2026
On July 19丨Zhi Xiang Jintai (688443.SH) announced that the lockdown period for the company's pre-IPO shares held by the actual controller and controlling shareholder of the company will be automatically extended for 6 months until December 19, 2026 (before the company's profit, the holdings of pre-initial shares will not be reduced within 3 full fiscal years from the date of listing of the company's shares). The lockdown period for the company's pre-IPO shares held by directors, senior management, and core technical personnel is automatically extended for 6 months until December 19, 2024 (before the company makes a profit, within 3 full fiscal years from the date of listing of the company's shares, there will be no reduction in initial holdings
Zhi Xiang Jintai (688443.SH): Plans to use no more than 2 billion yuan of temporary idle funds raised for cash management
On July 19, GLONGHUI | Zhixiang Jintai (688443.SH) announced that the company plans to use no more than RMB 2 billion (including principal amount) of temporarily idle funds raised for cash management. The period of use shall not exceed 12 months. Funds can be used on a rolling basis within the above limits and periods.
Zhi Xiang Jintai: How do innovative pharmaceutical companies determine a market-based sample of valuations
“Investor Network” Cai Jun Recently, Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. (hereinafter referred to as “Zhixiang Jintai”, “Company”, 688443.SH) completed pricing before listing on the Science and Technology Innovation Board. As an innovative pharmaceutical company, there are many topics surrounding Zhixiang Jintai, especially high prices and high valuations. However, in fact, whether an enterprise has the ability to truly innovate, the prospects for R&D and commercialization are the key. There are many cases where loss-making innovative pharmaceutical companies go public on the Science and Technology Innovation Board. Among them, BeiGene's market value exceeded 100 billion yuan after listing, and Shenzhou Cell exceeded 20 billion yuan. These companies are still losing money, but because of cutting-edge R&D technology and differentiation
Analysis
Price Target
No Data
